 LEIDEN, Netherlands CAMBRIDGE, Mass., April 13, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq:PRQR, a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the publication in the scientific journal Nature Medicine titled Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report describing durable vision improvement after treatment with sepofarsen in a clinical trial for CEP290 mediated Leber congenital amaurosis 10 LCA10. 